Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib Combinations in Metastatic Triple Negative Breast Cancer
NCT03853707Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jun 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ipatasertib in triple-negative breast cancer (TNBC), sponsored by City of Hope. Started Jun 2019; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03853707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853707.